ATP7B

Across TCGA pan-cancer cohorts, ATP7B Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ATP7B data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ATP7B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP7B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THYM, UCEC, and BRCA are the cancer types where ATP7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.941	0.620	.005	36	view →
BRCA	OS	Median	All	0.652	0.964	<.001	34	view →
STAD	OS	Median	All	0.144	0.547	.025	12	view →
TGCT	DFS	Median	All	0.146	0.801	.020	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.671	0.893	.019	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	II,III,IV	0.479	0.294	.027	3	view →
THCA	OS	Median	All	0.671	0.955	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ATP7B–THYM (OS)

Open the THYM breakdown →